ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO1009

Mapping CKD Prevalence Burden in a Reportedly High Australian Health District Region

Session Information

Category: CKD (Non-Dialysis)

  • 2301 CKD (Non-Dialysis): Epidemiology, Risk Factors, and Prevention


  • Cheikh Hassan, Hicham I., University of Wollongong Faculty of Science Medicine and Health, Wollongong, New South Wales, Australia
  • Lambert, Kelly, University of Wollongong, Wollongong, New South Wales, Australia
  • Moules, Stephen, University of Wollongong, Wollongong, New South Wales, Australia
  • Mcalister, Brendan J., Illawarra Shoalhaven Local Health District, Wollongong, New South Wales, Australia
  • Murali, Karumathil, University of Wollongong Faculty of Science Medicine and Health, Wollongong, New South Wales, Australia

Chronic kidney disease (CKD) affects 10% of the worldwide population but varies globally and regionally. In Australia, it ranges from 3% to 20%, with reports indicating a high prevalence of almost 20% among Illawarra and Shoalhaven Local Health District (ISLHD) residents. We aimed to determine the true prevalence of CKD among ISLHD residents and to identify potential risk factors.


Retrospective cohort longitudinal analysis on data from adult patients (>18 years of age), who attended an ISLHD facility between January 2008 and December 2017. Data variables included baseline demographics, comorbidities (defined from international classification of disease [ICD 10AM]), and CKD status defined using ICD-10AM codes or two creatinine or urine protein measurements, within 3-12 months apart, confirming CKD as per Kidney Disease Improving Global Outcome (KDIGO) definitions. Proportion of CKD in each suburb was calculated to identify suburbs with low and high prevalence of CKD. We preformed multivariate Cox proportional hazard analysis to determine CKD risk among the ISLHD suburbs, using time to CKD as an endpoint. Variables known to influence CKD risk (such as age, diabetes, hypertension, history of acute kidney injury) were included in the analysis.


In total 135,585 patients were followed up for 580,118 patient years. Mean age was 53 (standard deviation 21.2) years and the most common comorbidity was hypertension (26%), diabetes (14%) and coronary artery disease (10%). CKD affected 9% of the population with an incidence of 2 per 100 patient year. CKD patients were more likely to have, compared to non-CKD patients, a history of hypertension (43% vs 25%) diabetes (18% vs 12%) and acute kidney injury (20% vs 9%), P<0.001. The CKD prevalence differed highly across the 80 suburbs within the region, ranging from 4% to 24%. However, multivariate cox regression analysis which included risk factors known for CKD, found none of the suburbs had a statistically significant CKD risk above the known average.


Despite reports to the contrary, ISLHD CKD prevalence is within the national average. The large variability among the ISLHD suburbs can be explained by known risk factors and older age.